RxDoctor Payments Data

Sarah Darbandi, MD

Ophthalmology · Jacksonville, FLNPI 1972777936

Payments from drug & device makers

$45,444in general payments, 2019–2025

Across 311 payments — averaging $146.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$30K
  • AbbVie$5K
  • Kala Pharmaceuticals, Inc.$5K
  • Sun Pharmaceutical Industries Inc.$1K
  • Bausch & Lomb Americas Inc.$862
  • Amgen$465
  • plus $4K from 23 others

What the payments were for

  • Consulting fees$5,25012%
  • Speaking & faculty fees$21,37547%
  • Grants$1,0432%
  • Travel & lodging$4,90611%
  • Food & beverage$12,32227%
  • Education$5481%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,444 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$227,167
Medicare patients
359
Services billed
3,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine136$133,691
XdemvyLotilaner21$38,686
MieboPerfluorohexyloctane/Pf35$25,790
LumiganBimatoprost40$21,669
XiidraLifitegrast13$20,311
Alphagan PBrimonidine Tartrate41$14,824
TyrvayaVarenicline Tartrate20$14,573
Cyclosporine21$9,745
Loteprednol Etabonate60$9,085
LotemaxLoteprednol Etabonate18$5,894
Prednisolone Acetate118$5,472
ProlensaBromfenac Sodium14$4,984
VyzultaLatanoprostene Bunod12$4,862
Brimonidine Tartrate72$4,144
RocklatanNetarsudil Mesylat/Latanoprost11$3,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$4,765$170,183217 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$862$50,96260 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$242$38,68621 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax, Prolensa$430$19,96492 claims
Oyster Point Pharma, Inc.Tyrvaya$456$14,57320 claims
Aerie Pharmaceuticals, Inc.Rocklatan$11$3,81511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →